REDX
PHARMA PLC
("Redx"
or the "Company")
Update on
AIM Delisting
Alderley Park, UK, 29 April
2024 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease and cancer today provides a further
update with respect to the cancellation of the admission of its
ordinary shares of 1 pence each (the "Ordinary Shares") to trading on AIM
(the "AIM Delisting"), as
originally announced on 2 April 2024.
As previously announced, the last
day of trading in the Ordinary Shares on AIM will be 30 April 2024
and the AIM Delisting will become effective at 7:00 a.m. on 1 May
2024. Details of the matched bargain facility to be provided by J P
Jenkins to assist shareholders wishing to trade in Ordinary Shares
following the AIM Delisting will be available on the Company's
website www.redxpharma.com.
The matched bargain facility will be effective
from 7:30 a.m. on 1 May 2024.
Following the AIM Delisting, SPARK
Advisory Partners Limited will cease to act as nominated adviser
and Panmure Gordon (UK) Limited will cease to act as broker to the
Company.
|
For
further information, please contact:
|
|
|
|
|
|
|
|
Redx Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
Matt Davis/Adam Dawes
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Broker)
|
T: +44 (0)207 886 2500
|
|
Rupert Dearden/Freddy Crossley/Emma
Earl
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
Simon Conway/Ciara Martin
|
|
|
|
|
|
|
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company expects a
number of data points during 2024 including from lead fibrosis
product candidate, the selective ROCK2 inhibitor, zelasudil
(RXC007), in development for interstitial lung disease and
currently undertaking a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a
GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is in Phase 1 development and is expected to
report healthy volunteer data; and Redx's lead oncology product
candidate, the Porcupine inhibitor zamaporvint (RXC004), being
developed as a targeted treatment for Wnt-ligand dependent cancers,
is expected to report anti-PD-1 combination Phase 2 data, following
which Redx will seek a partner for ongoing development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
